Novavax's New Covid-19 Vaccine Might Be Late to the Party

Novavax shares jumped 5.4% Wednesday after the agency’s vaccine expert panel voted to recommend its two-dose vaccine. It is quite the victory for the 35-year-old Maryland biotech, which was running out of cash in late 2019 before the pandemic came to its rescue. But the nod from the expert group comes as the pool of Americans seeking a booster shot continues to nosedive. The seven-day average for booster shots administered daily was about 55,600 this week, down from over a million in early December, according to data from the Centers for Disease Control and Prevention. The agency says only about half of booster-eligible people have gotten one so far—a clear sign of vaccine fatigue.